| Filed On | Filing |
|---|---|
| 13 Aug 2026 |
8-K/A: Results of Operations and Financial Condition; Regulation FD Disclosure
Defined terms included below shall have the same meaning as terms defined and included elsewhere in the Combined Company’s (as defined below) Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) o... |
| 14 Jan 2022 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On January 12, 2022 (the “Effective Date”), VYNE Therapeutics Inc. (the “Company” or “VYNE”) entered into an Asset Purchase Agreement (the “Agreement”) with Journey Medical Corporation (“Journey” or “Buyer”) pursuant to which the Company... |
| 07 May 2020 |
8-K/A: Financial Statements and Exhibits
We have audited the accompanying consolidated balance sheets of Foamix Pharmaceuticals Ltd. and its subsidiary (the “Company”) as of December 31, 2019 and 2018, and the related consolidated statements of operations, comprehensive loss, c... |
Loading...